P. A. Philip - Concepedia

Author

P. A. Philip

The Barbara Ann Karmanos Cancer Institute

Also Known As

P A Philip, P Philip, P. A. Philip, P. Philip, P.A Philip, P.A. Philip, PA Philip, Philip A Philip, Philip A. Philip, Princemon Philip

134

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

The Barbara Ann Karmanos Cancer Institute Wayne State University Mayo Clinic in Arizona Churchill Hospital University of Michigan

About

P. A. Philip is an author at The Barbara Ann Karmanos Cancer Institute specializing in medicine, oncology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	32	1.3K
2	Health Sciences	4	4	261
3	Cell Biology	3	3	133
4	Engineering	1	1	117
5	Biochemistry	1	1	16

P. A. Philip

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Phase I Study of Bryostatin 1: Assessment of Interleukin 6 and Tumor Necrosis Factor Induction In Vivo P. A. Philip, Daniel Rea, P. Thavasu, JNCI Journal of the National Cancer Institute	1993	187
Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study P. A. Philip, Jacqueline Benedetti, Cecilia M. Fenoglio‐Preiser, Journal of Clinical Oncology Surgical OncologyCancer ManagementAdjuvant ChemotherapyPathologyPancreatic Cancer	2007	187
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh, Annals of Oncology Advanced EsophagealSurgical OncologyEsophagusEsophageal CancerGastroesophageal Junction	2016	143
MicroRNA profiling of diagnostic needle aspirates from patients with pancreatic cancer S. Ali, Husain A. Saleh, Sean K. Sethi, British Journal of Cancer Microrna ProfilingTumor BiologyEngineeringPancreatic CancerMedicine	2012	117
A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers Bassel F. El‐Rayes, Mark M. Zalupski, T. Bekai-Saab, Annals of Oncology Esophageal CancerGastrointestinal OncologyMedicineGastroesophageal Junction CancersPharmacology	2010	97
Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer Omar Soubani, Ashhar Ali, Farah Logna, Carcinogenesis	2012	96
A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer. Jeffrey A. Zonder, Anthony F. Shields, Mark M. Zalupski, PubMed Tumor BiologyPhase Ii TrialProtein Kinase CGastrointestinal OncologyMedicine	2001	82
A phase II trial of gefitinib in patients (pts) with progressive metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study Timothy J. Hobday, Kyle D. Holen, Ross C. Donehower, Journal of Clinical Oncology UrologyPhase Ii ConsortiumPhase Ii TrialEndocrine-related CancerMedicine	2006	62
High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines NSA Stuart, P. A. Philip, Katia Tonkin, British Journal of Cancer MedicinePharmacologyBreast CancerPharmacotherapyHigh-dose Tamoxifen	1992	61
A phase II study of carboplatin and paclitaxel in esophageal cancer B. F. El-Rayes, Anthony F. Shields, Mark M. Zalupski, Annals of Oncology Esophageal CancerMedicinePharmacologyPathologyPhase Ii Study	2004	51

Page 1